Schering-Plough Reports Data From SAPHRIS asenapine Long-Term Schizophrenia Relapse Prevention Study

Schering-Plough Corporation (NYSE:SGP) reported final results of a SAPHRIS® (asenapine) long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the primary efficacy endpoint, was significantly longer with SAPHRIS than with placebo (P < 0.0001). At the end of the double-blind phase, significantly fewer patients had relapsed with SAPHRIS than with placebo, 12 percent vs. 47 percent (P < 0.0001). In addition, the time to treatment discontinuation for any reason, a secondary efficacy assessment, was significantly longer with SAPHRIS than placebo (P < 0.001). These results were presented at a major...

Want to see the full article?

• Purchase this article for only $3.00